Cellectar Biosciences Statistics
Share Statistics
Cellectar Biosciences has 41.27M shares outstanding. The number of shares has increased by 235.85% in one year.
| Shares Outstanding | 41.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 15.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 40.04M |
| Failed to Deliver (FTD) Shares | 143.99K |
| FTD / Avg. Volume | 6.24% |
Short Selling Information
The latest short interest is 1.84M, so 4.45% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short % of Shares Out | 4.45% |
| Short % of Float | 4.58% |
| Short Ratio (days to cover) | 8.34 |
Valuation Ratios
The PE ratio is -0.89 and the forward PE ratio is -0.76.
| PE Ratio | -0.89 |
| Forward PE | -0.76 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | -2.23 |
| P/FCF Ratio | -1.02 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cellectar Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.41, with a Debt / Equity ratio of 0.
| Current Ratio | 0.41 |
| Quick Ratio | 0.41 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 2.51% and return on capital (ROIC) is 266.32%.
| Return on Equity (ROE) | 2.51% |
| Return on Assets (ROA) | -3.15% |
| Return on Capital (ROIC) | 266.32% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.90M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -60.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -92.7% in the last 52 weeks. The beta is 1.01, so Cellectar Biosciences 's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -92.7% |
| 50-Day Moving Average | 1.1 |
| 200-Day Moving Average | 2.24 |
| Relative Strength Index (RSI) | 19.3 |
| Average Volume (20 Days) | 2.31M |
Income Statement
| Revenue | n/a |
| Gross Profit | -192.38K |
| Operating Income | -38.96M |
| Net Income | -37.98M |
| EBITDA | -38.77M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.11 |
Balance Sheet
The company has 9.56M in cash and 552.98K in debt, giving a net cash position of 9.01M.
| Cash & Cash Equivalents | 9.56M |
| Total Debt | 552.98K |
| Net Cash | 9.01M |
| Retained Earnings | -217.48M |
| Total Assets | 37.29M |
| Working Capital | 15.58M |
Cash Flow
In the last 12 months, operating cash flow was -32.38M and capital expenditures -864.04K, giving a free cash flow of -33.24M.
| Operating Cash Flow | -32.38M |
| Capital Expenditures | -864.04K |
| Free Cash Flow | -33.24M |
| FCF Per Share | -2.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1151.85% |
| FCF Yield | -298.21% |
Analyst Forecast
The average price target for CLRB is $28, which is 10270.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $28 |
| Price Target Difference | 10270.4% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 22, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 22, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -12.87 |
| Piotroski F-Score | 2 |